Wikipedia

Commonly prescribed drugs

Commonly prescribed drugs are drugs that are frequently provided by doctors in a prescription to treat a certain disease. These drugs are often first-line treatment for the target diseases and are effective in tackling the symptoms. An example of the target disease is ischemic heart disease. Some examples of commonly prescribed drugs for this disease are beta-blockers, calcium-channel blockers and nitrates.

In accordance with the pharmacological effects, commonly prescribed drugs can be divided into different groups. Drugs in the same group exert nearly identical effects, and can be utilized for treating the prevailing disease and sometimes, preventing complications of the existing diseases.

The use of commonly prescribed drugs can be reflected from the number of prescriptions of the drugs. Countries have their own dataset in recording the trend of commonly prescribed drugs. For example, the United States uses the Medical Expenditure Panel Survey (MEPS)[1] and England uses the English Prescribing Dataset[2] to record the prescription data for showing which drugs are commonly prescribed.

Understanding commonly prescribed drugs allows healthcare professionals to react to symptoms quickly and new treatment strategies can be developed. However, the data for commonly prescribed drugs may be outdated due to the time lag between data collection and publication as well as errors in data collection process.

History

edit

Commonly prescribed drugs are prescribed according to guidelines around the world. For instance, for ischemic heart disease, the American College of Cardiology/American Heart Association (ACC/AHA) guideline is used in the United States and the European Society of Cardiology (ESC) guideline is used in Europe. Western guidelines are more commonly used for reference during the development of local practice guidelines due to the large number of western guidelines stored in guideline databases.[3] The data of prescriptions are collected through the government, such as Medical Expenditure Panel Survey (MEPS) in America and the Pharmaceutical Benefit Scheme (PBS) in Australia, providing information on the actual prescription volume of drugs.

The United States

edit

The Medical Expenditure Panel Survey (MEPS) conducted by the Agency for Healthcare Research and Quality (AHRQ) via the United States government is used to collect prescription data and data for other healthcare services, including home healthcare, children's health and preventive care in America. The survey started in 1996 and was the predecessor of the National Medical Expenditure Survey (NMES) and the National Medical Care Utilization and Expenditure Survey (NMCUES),[4] which were conducted in 1977 (NMES-1), 1980 (NMCUES), and 1987 (NMES-2). The survey is updated every year with the renewed data from the country. The prescription data is published in the Prescribed Medicines File of the MEPS.[5] The collection of data involves two components: Household component and the Medical Provider component. The household component collects self-reported data of the prescribed medicines and the demographic information of the respondents. The Medical Provider component acts as a piece of follow-back information provided by the pharmacy including a computerized printout for all prescription filled for the patient.[6]

The United Kingdom

edit

The English Prescribing Dataset (EPD) from the NHS Business Services Authority (NHSBSA) provides prescription data in the United Kingdom.[2] The dataset was created in 2014. EPD is a combination of the Detailed Prescribing Information (DPI) and the Practice Level Prescribing in England (PLP). Both DPI and PLP are previous datasets from NHSBSA and NHS Digital respectively and EPD aims to replace them both in the future, but no specific date of replacement is given. EPD collects data from England, Wales, Scotland, Guernsey, Alderney, Jersey and the Isle of Man. EPD provides the item, quantity, net ingredient cost, actual cost, average daily quantity (ADQ), practice name and address details of the prescription.[7]

Australia

edit

The Pharmaceutical Benefits Scheme (PBS) from the Australian Government Department of Health provides the prescription data of prescriptions under PBS. PBS started in 1948 and the under co-payment prescriptions were added into the dataset from 1 April 2012. It publishes the PBS expenditure and prescriptions report every year recording prescription data in the past 12 months. The examples of data it provides are the top 50 drugs by total prescription volume and the top 50 drugs by government cost.[8]

Benefits and limitations

edit

Benefits

edit

Understanding commonly prescribed drugs for different diseases can allow healthcare professionals to be more confident and decisive when choosing the most suitable treatment for the patient. This can also help develop new treatment strategies by researchers for more effective treatments.[9] By enriching the knowledge of commonly prescribed drugs, pharmacy students will be more familiar with their mechanism of action, first-line therapy indications and side effects.[10]

Limitations

edit

Limitations include time lag for the conducted survey. The Medical Expenditure Panel Survey (MEPS) shows data recorded two years before the publishing of the survey. The time lag may lead to a difference in representing the current prescribing practice with the recorded data in the survey. Questionnaires which are self-reported tend to create recall bias. Respondents are likely to underreport the number of prescription drugs they have as those drugs are usually for short-term use and intermittent use, such as analgesics and topical agents.[11]

Examples of commonly prescribed drugs

edit

Two diseases from the top 10 causes of death introduced by the World Health Organization (WHO) in 2019 are used as examples, namely ischemic heart disease (ranked 1st) from cardiovascular diseases and Chronic Obstructive Pulmonary Disease from respiratory diseases (ranked 3rd).[12] Although stroke is ranked 2nd by WHO, drugs used are similar to ischemic heart disease. Moreover, surgical interventions are commonly required, so it will be out of the scope of this article and it will not be introduced.[13][14]

Ischemic Heart Disease  

edit
Main article: Coronary Heart Disease

Ischemic Heart Disease (IHD) or coronary heart disease is the lack of supply of blood to an area in the heart, often due to plaque formation (atherosclerosis), causing inadequacy of oxygen to heart muscle and eventually leading to myocardial infarction. This disease can be classified into acute and chronic coronary heart disease. This disease caused 8.9 million deaths in 2019 and was ranked 1st in the top 10 causes of death globally by the World Health Organization (WHO).[12]

The treatment of Ischemic Heart Disease can be divided into two directions: risk factor control and symptomatic relief.

Commonly prescribed drugs for Ischemic Heart Disease

Types of drug Common Examples Mechanism of benefit and effect Side effects, caution & contraindications Remarks
Beta-blockers Block beta-1 receptors in the heart → stop the effects of catecholamines on the heart→ reduce heart rate, heart contractility and conduction velocity → reduce the workload of the heart[15] Side effects[16]
  • Aim to control heart rate to 55-60 beats per minute at rest[17]
  • Used for symptomatic relief
     
    An image of metoprolol (Betaloc)
Caution
  • Reduce the dose gradually over 2–3 weeks when withdrawing to avoid ischemia and myocardial infarction
Contraindications
Calcium Channel Blockers (CCB) Dihydropyridine (DHP) CCB: Block L-type calcium channels in arterial smooth muscle cells → reduce vasoconstriction → reduce arterial blood pressure[18] Side effects[19]
  • Avoid intake of food that interacts with CYP3A4, such as grapefruit and pomelo[16]
  • Used for symptomatic relief
     
    An image of amlodipine tablets package (Norvasc)
Contraindications
  • HFrEF (for nifedipine)
  • Obstructive myopathy
Non-DHP CCB: Block L-type calcium channels in the myocardium → decrease heart rate and contractility[18] Side effects
  • Bradycardia
  • Hypotension
  • Heart block
Contraindications
  • HFrEF
  • Bradycardia
  • Sick sinus syndrome
Caution
  • CCB are CYP3A4 inhibitors, especially non-DHP CCB
Nitrates Metabolized in body → release nitric oxide → increase cyclic guanosine monophosphate (cGMP) → vasodilating effects predominant on veins and epicardial coronary vessels → decrease preload, myocardial wall tension and increase blood flow to heart[20] Side effects[21]
  • Sublingual nitroglycerin is used for acute coronary syndrome
  • Isosorbide mononitrate and isosorbide dinitrate are used for symptomatic relief when blood pressure <130/80 mmHg[17]
  • Not to be used as monotherapy in chronic coronary syndrome
 
An image of sublingual nitroglycerin tablets (Nitrostat)
Caution
  • Avoid concomitant use of PDE-5 inhibitors
  • A nitrate-free period for 10–14 hours every day to prevent nitrate tolerance
Contraindications
Non-steroidal

anti-inflammatory drugs (NSAID)

Block cyclooxygenase-1→ reduce thromboxane A2 production → reduce platelet activation and aggregation → reduce plaque formation and risk of adverse cardiovascular events[22] Side effects[23]
  • Increased bleeding risk, especially in the stomach
  • Gastrointestinal irritation
  • Used in risk factor control and acute coronary syndrome
  • Dual antiplatelet therapy with P2Y12 inhibitors for a reduction of risk of major adverse cardiac events for all acute coronary syndrome patients[24]
  • Concomitant use with proton pump inhibitors is recommended for patients who are at a high risk of gastrointestinal bleeding[17]
  • Use at low dose: 75–100 mg orally once a day
 
An image of low-dose aspirin tablets (Gericare)
Caution
  • History of gastrointestinal bleeding
Contraindications
P2Y12 Inhibitors Block P2Y12 receptors on platelets → prevent platelet activation by adenosine monophosphate (ADP) → prevent aggregation of platelets and plaque formation[25] Side effects[23]
  • Increased bleeding risk
  • Rash (Clopidogrel)
  • Dual antiplatelet therapy with aspirin for a reduction of risk of major adverse cardiac events for all acute coronary syndrome patients[24]
 
An image of clopidogrel tablet package (Plavix)
Caution
  • Metabolism of P2Y12 inhibitors requires CYP450 enzymes → potential drug interactions
Contraindications
  • Prasugrel
    • Stroke
    • Older than 75 years old
    • Lighter than 60 kg
Statins Side effects[27]
  • Used for risk factor control
  • If the maximum dose of statin cannot achieve the patient's goal, combination with ezetimibe is recommended.[17]
 
An image of rosuvastatin tablets (Crestor)
Caution
  • Atorvastatin and simvastatin are metabolized by CYP450 enzymes, leading to CYP450 enzymes related potential drug interactions
Contraindications
  • Active liver disease
  • Pregnancy or breastfeeding
  • Unexplained persistent increase of liver function test results

Chronic Obstructive Pulmonary Disease (COPD)

edit

Chronic Obstructive Pulmonary Disease (COPD) is a disease that causes chronic respiratory problems by gradually blocking the respiratory tracts. The continuous exposure to toxic fumes produced by cigarettes, vehicle engines and other human activities leads to inflammation of the respiratory tract, causing the development of COPD. The problem will deteriorate over time if it is not well managed. It will eventually cause respiratory failure and death in the late stage.[28] It is the third deadliest disease reported by WHO in 2019 and it accounted for 6% of total deaths.[12]

There are two types of management plan in COPD, namely regular treatment and acute exacerbation. In acute exacerbation, new medications will be added to the existing prescription and they will be stopped once the exacerbation is managed.

Types of drug[28] Common Examples[28] Mechanism of benefit and the effect Side effect, caution & contraindications Remarks
Short-acting beta2-agonist (SABA) Bind and activate beta2 adrenergic receptor on smooth muscles of respiratory tract → rise in cyclic AMP (cAMP) level in smooth muscle → relaxation of the smooth muscle[29] Side effect[29][30]
  • Quick relief of symptoms
  • FEV1 improvement is seen
  • Use when needed
  • Can be used in regular treatment and acute exacerbation
  • Effect only last for 4 – 6 hours for SABAs and 6–9 hours for SAMAs[28]
  • Provided in inhalers → techniques for usage is important for management of COPD[31]
  • Muscarinic antagonist can be considered as more effective than beta2 agonist → reduce the high vagal tone in patients[29]
 
An image of salbutamol inhaler.
Caution[32]
Contraindications[32]
  • Hypersensitivity to the active drug or the excipients
Short-acting muscarinic antagonist (SAMA) Interact with and block M3 muscarinic receptor on smooth muscles of respiratory tract → reduce acetylcholine activating postsynaptic  M3 muscarinic receptor at neuromuscular junction → reduce bronchoconstriction ⇒ bronchodilation[29] Side effects[29]
  • Generally not common → local action on airway smooth muscle
  • Most anticholinergic side effects as shown in atropine
Caution
Contraindications[33]
Long-acting beta2-agonist (LABA) Refer to SABA Side effects and Contraindications
  • Refer to SABA
  • More preferred in regular treatment
  • Very long duration of action (12–24 hours)
  • Huge improvement in lung function and symptoms
  • Risk of exacerbation greatly lowered → LAMA more prominent than LABA
  • Provided in inhalers → techniques for usage is important for management of COPD[31]
Caution[28]
  • Should not be used in acute exacerbation for rapid relieve of symptoms
Long-acting muscarinic antagonist (LAMA) Refer to SAMA Side effects and Contraindications
  • Refer to SAMA
Caution[28]
  • Should not be used in acute exacerbation for rapid relieve of symptoms
Methylxanthines
  • Inhibit PDEs in smooth muscle → reduce cAMP clearance → bronchodilation
  • Antagonize adenosine receptor → maintain sympathetic nervous system activity → bronchodilation[29][34]
  • Methylxanthines also tackle inflammation but the exact mechanism is not clearly known[35]
 Side effects[29]
  • Headache
  • Nausea / vomiting
  • Abdominal discomfort
  • Restlessness
  • Increased acid secretion
  • Arrhythmias at high dose
  • Narrow therapeutic range
  • Avoid drugs inducing / inhibiting CYP1A2 and CYP2E1[36]
Caution[36]
  • Metabolised by CYP1A2 and CYP2E1
  • Smoking can induce methylxanthine metabolism
Contraindications[36]
  • Hypersensitivity to xanthines
Inhaled corticosteroid (ICS) Act on airway smooth muscle cells by activating intracellular glucocorticoid receptor → modifying gene expression in the cells Side effects[29][36]
  • Not for monotherapy → commonly use in combination[28]
  • Provided in inhalers → techniques for usage is important for management of COPD[31]
  • Rinsing mouth with water, gargle and spit the water out, together with using MDIs with spacer can reduce oral thrush[36]
Also act by enhancing the effect of beta2 agonists → correct and prevent the desensitization of beta2 receptors[29] Caution[29]
  • Should not abruptly stopping treatment
Contraindications
  • No known contraindications due to local action
Phosphodiesterase-4 (PDE4) inhibitor Selectively blocking PDE4 on airway smooth muscles → increase intracellular cAMP level → induce action of protein kinase A → modulate inflammatory cytokine biosynthesis → reduce inflammation[38] Side effects[36]
  • Diarrhea
  • Nausea
  • Headache
  • Weight loss
  • Psychiatric disturbance → suicidal thoughts
  • Not for rapid relief of symptoms
  • Reduce risk of exacerbation
  • Improved lung function is observed[28]
Caution
  • Metabolised by CYP3A4 and CYP1A2[36]
  • Patient with history of depression / suicidal thought /action should be carefully examined and weight the risk and benefit of the administration[39]
Contraindications
  • Moderate to severe liver impairment[39]
Mucolytics Cleavage of S-S disulphur bond interlinking mucin polymer in the mucus → thinning the mucus and easier to be coughed out[40] Side effects[41][42]
  • Headache
  • Diarrhea
  • Stomach pains  
  • Used in acute exacerbation
  • Beneficial to patients not having ICS only[28]
Caution[41][42]
  • History of stomach ulcers
Contraindications[41][42]
  • Allergy to the active pharmaceutical product or any excipients inside
  • Active peptic ulcer
Systemic corticosteroids Refer to ICS Side effects[29][43]
  • Used in acute exacerbation
  • Usually used for 5 days
  • Can be used orally or by intravascular injection
  • It can be abruptly discontinued without any tapering[28]
Caution[29]
  • Should not abruptly stopping treatment
Contraindications[43]
  • Systemic fungal infections
  • More but not common in short term usage
Antibiotics Amoxicillin[44][45][46]
  • Interact with penicillin-binding proteins → prevent peptidoglycan layer formation in the bacteria → bacteria lack of protection and burst due to water absorption

Clavulanic acid[45][46]

  • Block beta-lactamase activity in bacteria → restore activity of penicillin-like antibiotics

Macrolides[45][46][47][48]

Tetracycline[45][46][47][49]

  • Interact with ribosomal 30-S subunit of bacteria → prevent bacterial protein synthesis
 
An image showing mechanism of action of antibiotics
 Side effects[44][47]
  • For all antibiotics
    • Disturbance of gastrointestinal system (e.g. diarrhea and nausea) due to the effect on gut microflora.
  • Amoxicillin / clavulanic acid[44][50]
    • Allergic reactions if allergic to penicillin
  • Macrolides[47]
  • Tetracyclines[47]
  • Used in acute exacerbation
  • 5–7 days of treatment is considered
  • Risk of exacerbation can be lessen by regular use of macrolides
  • Only be used when the patient experience three cardinal symptoms of COPD exacerbation: worsening dyspnea, increasing sputum production and purulence[28]
Caution[44][47]
  • Change to other type if allergic to specific type
  • Possible drug interactions
  • Avoid tetracycline when there is pre-existing renal or hepatic impairment
  • Dose adjustment needed for amoxicillin / clavulanic acid in patients with renal impairment
Contraindications[44][47]
  • Pregnancy (for tetracycline)
  • Allergy

Combination inhalers

edit
 
An image of different types of inhalers.

In patients with COPD, multiple inhalers need to be used at a time. There are two major types of inhaler, namely dry-powder inhaler(DPI) and metered-dose inhaler(MDI), and many more subtypes with different techniques for using them.[51] Adherence is also an issue with the use of multiple inhalers. Generally with different types of inhalers, the adherence will be lowered.[52][53] Proper inhaler technique and adherence are two of the factors that affect the management of COPD. Other factors include smoking cessation and participation in physical activities, to name but a few.[54] With inappropriately applied inhaler technique and low adherence, there will be ineffective management of COPD, thus increasing in the burden on the healthcare sector.[31][55] As a result, inhalers combining multiple medications are invented to tackle the problem.

Medication combined[28] Examples[28] Benefits[28]
SABA+SAMA
  • The improvement in symptoms and FEV1 is greater than the use of SABA or SAMA alone
LABA+LAMA
  • Lower rate of acute exacerbation when used in combination
  • Less symptoms and better improvement in lung function
ICS+LAMA
  • Perform better than individual medication to improve lung function
  • Better health status is obtained compared to individual medications
  • Greater reduction in risk of exacerbation than ICS or LAMA solely
LABA+LAMA+ICS
  • Better improvement of lung function and symptom
  • Obtaining better health status
  • Larger decline in exacerbation risk than all combined inhalers and LAMA.

References

edit
  1. ^ "Medical Expenditure Panel Survey Background". meps.ahrq.gov. Retrieved 2021-03-30.
  2. ^ a b "English prescribing data (EPD) | NHSBSA". www.nhsbsa.nhs.uk. Retrieved 2021-03-12.
  3. ^ Chen, Yaolong; Wang, Chen; Shang, Hongcai; Yang, Kehu; Norris, Susan L (5 February 2018). "Clinical practice guidelines in China". BMJ. 360: j5158. doi:10.1136/bmj.j5158. PMC 5797982. PMID 29437564.
  4. ^ "Medical Expenditure Panel Survey Background". meps.ahrq.gov. Retrieved 2021-03-12.
  5. ^ "MEPS HC-206A". www.meps.ahrq.gov. Retrieved 2021-03-12.
  6. ^ "Methodology Report #12: Outpatient Prescription Drugs: Data Collection and Editing in the 1996 MEPS (HC-010A)". meps.ahrq.gov. Retrieved 2021-03-12.
  7. ^ "English prescribing data (EPD) | NHSBSA". www.nhsbsa.nhs.uk. Archived from the original on 2020-08-13. Retrieved 2021-03-12.
  8. ^ Health, Australian Government Department of, Pharmaceutical Benefits Scheme (PBS) | PBS Expenditure and Prescriptions Report 1 July 2019 to 30 June 2020, Australian Government Department of Health, retrieved 2021-03-12
  9. ^ Fuentes, Andrea; Pineda, Moises; Venkata, Kalyan (14 May 2018). "Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice". Pharmacy. 6 (2): 43. doi:10.3390/pharmacy6020043. PMC 6025009. PMID 29757930.
  10. ^ Santee, Jennifer (September 2003). "A Web-Based Practice Examination to Improve Student Performance Concerning the 200 Most Prescribed Drugs" (PDF). American Journal of Pharmaceutical Education. 67 (4): 102. doi:10.5688/AJ6704102. S2CID 55425323. ProQuest 211222830. Archived from the original (PDF) on 8 August 2017.
  11. ^ Hill, Steven C.; Zuvekas, Samuel H.; Zodet, Marc W. (August 2011). "Implications of the Accuracy of MEPS Prescription Drug Data for Health Services Research". INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 48 (3): 242–259. doi:10.5034/inquiryjrnl_48.03.04. PMID 22235548. S2CID 28138824.
  12. ^ a b c "The top 10 causes of death". www.who.int. Retrieved 2021-03-13.
  13. ^ Powers William J.; Rabinstein Alejandro A.; Ackerson Teri; Adeoye Opeolu M.; Bambakidis Nicholas C.; Becker Kyra; Biller José; Brown Michael; Demaerschalk Bart M.; Hoh Brian; Jauch Edward C. (2019-12-01). "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. 50 (12): e344–e418. doi:10.1161/STR.0000000000000211. PMID 31662037.
  14. ^ Hemphill, J. Claude; Greenberg, Steven M.; Anderson, Craig S.; Becker, Kyra; Bendok, Bernard R.; Cushman, Mary; Fung, Gordon L.; Goldstein, Joshua N.; Macdonald, R. Loch; Mitchell, Pamela H.; Scott, Phillip A.; Selim, Magdy H.; Woo, Daniel (July 2015). "Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. 46 (7): 2032–2060. doi:10.1161/STR.0000000000000069. PMID 26022637. S2CID 2525622.
  15. ^ Gheorghiade Mihai; Colucci Wilson S.; Swedberg Karl (2003-04-01). "β-Blockers in Chronic Heart Failure". Circulation. 107 (12): 1570–1575. doi:10.1161/01.CIR.0000065187.80707.18. PMID 12668487. S2CID 5288182.
  16. ^ a b "Stable Ischemic Heart Disease | Pharmacotherapy: A Pathophysiologic Approach, 11e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  17. ^ a b c d Knuuti, Juhani; Wijns, William; Saraste, Antti; Capodanno, Davide; Barbato, Emanuele; Funck-Brentano, Christian; Prescott, Eva; Storey, Robert F; Deaton, Christi; Cuisset, Thomas; Agewall, Stefan; Dickstein, Kenneth; Edvardsen, Thor; Escaned, Javier; Gersh, Bernard J; Svitil, Pavel; Gilard, Martine; Hasdai, David; Hatala, Robert; Mahfoud, Felix; Masip, Josep; Muneretto, Claudio; Valgimigli, Marco; Achenbach, Stephan; Bax, Jeroen J; Neumann, Franz-Josef; Sechtem, Udo; Banning, Adrian Paul; Bonaros, Nikolaos; Bueno, Héctor; Bugiardini, Raffaele; Chieffo, Alaide; Crea, Filippo; Czerny, Martin; Delgado, Victoria; Dendale, Paul; Flachskampf, Frank Arnold; Gohlke, Helmut; Grove, Erik Lerkevang; James, Stefan; Katritsis, Demosthenes; Landmesser, Ulf; Lettino, Maddalena; Matter, Christian M; Nathoe, Hendrik; Niessner, Alexander; Patrono, Carlo; Petronio, Anna Sonia; Pettersen, Steffen E; Piccolo, Raffaele; Piepoli, Massimo Francesco; Popescu, Bogdan A; Räber, Lorenz; Richter, Dimitrios J; Roffi, Marco; Roithinger, Franz X; Shlyakhto, Evgeny; Sibbing, Dirk; Silber, Sigmund; Simpson, Iain A; Sousa-Uva, Miguel; Vardas, Panos; Witkowski, Adam; Zamorano, Jose Luis; Achenbach, Stephan; Agewall, Stefan; Barbato, Emanuele; Bax, Jeroen J; Capodanno, Davide; Cuisset, Thomas; Deaton, Christi; Dickstein, Kenneth; Edvardsen, Thor; Escaned, Javier; Funck-Brentano, Christian; Gersh, Bernard J; Gilard, Martine; Hasdai, David; Hatala, Robert; Mahfoud, Felix; Masip, Josep; Muneretto, Claudio; Prescott, Eva; Saraste, Antti; Storey, Robert F; Svitil, Pavel; Valgimigli, Marco; Windecker, Stephan; Aboyans, Victor; Baigent, Colin; Collet, Jean-Philippe; Dean, Veronica; Delgado, Victoria; Fitzsimons, Donna; Gale, Christopher P; Grobbee, Diederick; Halvorsen, Sigrun; Hindricks, Gerhard; Iung, Bernard; Jüni, Peter; Katus, Hugo A; Landmesser, Ulf; Leclercq, Christophe; Lettino, Maddalena; Lewis, Basil S; Merkely, Bela; Mueller, Christian; Petersen, Steffen; Petronio, Anna Sonia; Richter, Dimitrios J; Roffi, Marco; Shlyakhto, Evgeny; Simpson, Iain A; Sousa-Uva, Miguel; Touyz, Rhian M; Benkhedda, Salim; Metzler, Bernhard; Sujayeva, Volha; Cosyns, Bernard; Kusljugic, Zumreta; Velchev, Vasil; Panayi, Georgios; Kala, Petr; Haahr-Pedersen, Sune Ammentorp; Kabil, Hamza; Ainla, Tiia; Kaukonen, Tomi; Cayla, Guillaume; Pagava, Zurab; Woehrle, Jochen; Kanakakis, John; Tóth, Kálmán; Gudnason, Thorarinn; Peace, Aaron; Aronson, Doron; Riccio, Carmine; Elezi, Shpend; Mirrakhimov, Erkin; Hansone, Silvija; Sarkis, Antoine; Babarskiene, Ruta; Beissel, Jean; Maempel, Andrew J Cassar; Revenco, Valeriu; de Grooth, G J; Pejkov, Hristo; Juliebø, Vibeke; Lipiec, Piotr; Santos, José; Chioncel, Ovidiu; Duplyakov, Dmitry; Bertelli, Luca; Dikic, Ana Djordjevic; Studenčan, Martin; Bunc, Matjaz; Alfonso, Fernando; Bäck, Magnus; Zellweger, Michael; Addad, Faouzi; Yildirir, Aylin; Sirenko, Yuriy; Clapp, Brian (14 January 2020). "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes". European Heart Journal. 41 (3): 407–477. doi:10.1093/eurheartj/ehz425. hdl:11379/537215. PMID 31504439.
  18. ^ a b Pearle, David L. (September 1990). "Pharmacologic management of ischemic heart disease with β-blockers and calcium channel blockers". American Heart Journal. 120 (3): 739–742. doi:10.1016/0002-8703(90)90046-z. PMID 1975155.
  19. ^ "UpToDate". www.uptodate.com. Retrieved 2021-03-29.
  20. ^ "Nitric Oxide | Basic & Clinical Pharmacology, 15e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  21. ^ DiPiro, Joseph T; Talbert, Robert L; Yee, Gary C; Matzke, Gary R; Wells, Barbara G; Posey, L Michael; Streetman, Daniel S; Streetman, Darcie-Ann D (February 2009). "Book Review: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition". Annals of Pharmacotherapy. 43 (2): 395. doi:10.1345/aph.1l477. S2CID 79160219.
  22. ^ "Drugs Used in Disorders of Coagulation | Basic & Clinical Pharmacology, 15e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  23. ^ a b "Acute Coronary Syndrome | Pharmacotherapy: A Pathophysiologic Approach, 11e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  24. ^ a b "ESC Guidelines on Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (Management of)". www.escardio.org. Retrieved 2021-03-14.
  25. ^ Shah, Rahman; Rashid, Abdul; Hwang, Inyong; Fan, Tai-Hwang M.; Khouzam, Rami N.; Reed, Guy L. (June 2017). "Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome". The American Journal of Cardiology. 119 (11): 1723–1728. doi:10.1016/j.amjcard.2017.03.011. PMID 28385176.
  26. ^ Almeida, Shone O.; Budoff, Matthew (November 2019). "Effect of statins on atherosclerotic plaque". Trends in Cardiovascular Medicine. 29 (8): 451–455. doi:10.1016/j.tcm.2019.01.001. PMID 30642643. S2CID 58668816.
  27. ^ "Agents Used in Dyslipidemia | Basic & Clinical Pharmacology, 15e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  28. ^ a b c d e f g h i j k l m n o "2021 GOLD Reports". Global Initiative for Chronic Obstructive Lung Disease – GOLD. Retrieved 2021-03-14.
  29. ^ a b c d e f g h i j k l Barnes, Peter J. (2017), Brunton, Laurence L.; Hilal-Dandan, Randa; Knollmann, Björn C. (eds.), "Pulmonary Pharmacology", Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13 ed.), New York, NY: McGraw-Hill Education, retrieved 2021-03-14
  30. ^ Cazzola, Mario; Page, Clive P.; Rogliani, Paola; Matera, M. Gabriella (April 2013). "β 2 -Agonist Therapy in Lung Disease". American Journal of Respiratory and Critical Care Medicine. 187 (7): 690–696. doi:10.1164/rccm.201209-1739PP. PMID 23348973.
  31. ^ a b c d Virchow, J.C.; Crompton, G.K.; Dal Negro, R.; Pedersen, S.; Magnan, A.; Seidenberg, J.; Barnes, P.J. (January 2008). "Importance of inhaler devices in the management of airway disease". Respiratory Medicine. 102 (1): 10–19. doi:10.1016/j.rmed.2007.07.031. PMID 17923402.
  32. ^ a b Abosamak, Nour Eldin R.; Shahin, Mohamed H. (2021), "Beta 2 Receptor Agonists/Antagonists", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32644495, retrieved 2021-03-14
  33. ^ a b Saab, Hussien; Aboeed, Ayham (2021), "Ipratropium", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31334981, retrieved 2021-03-14
  34. ^ Jilani, Talha N.; Preuss, Charles V.; Sharma, Sandeep (2021), "Theophylline", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30085566, retrieved 2021-03-14
  35. ^ Ito, Kazuhiro; Lim, Sam; Caramori, Gaetano; Cosio, Borja; Chung, K. Fan; Adcock, Ian M.; Barnes, Peter J. (25 June 2002). "A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression". Proceedings of the National Academy of Sciences. 99 (13): 8921–8926. Bibcode:2002PNAS...99.8921I. doi:10.1073/pnas.132556899. PMC 124399. PMID 12070353.
  36. ^ a b c d e f g "Chronic Obstructive Pulmonary Disease | McGraw-Hill's NAPLEX® Review Guide, 3e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  37. ^ Lemke, Thomas L.; Williams, David A. (2012-01-24). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. ISBN 978-1-60913-345-0.
  38. ^ Li, Heng; Zuo, Jianping; Tang, Wei (17 October 2018). "Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases". Frontiers in Pharmacology. 9: 1048. doi:10.3389/fphar.2018.01048. PMC 6199465. PMID 30386231.
  39. ^ a b Forest Pharmaceuticals, Inc. (2013). Daliresp (roflumilast) tablet: Highlights of prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022522s003lbl.pdf
  40. ^ Gupta, Rishab; Wadhwa, Roopma (2021), "Mucolytic Medications", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32644589, retrieved 2021-03-14
  41. ^ a b c Ennogen Healthcare. (2019) Acetylcysteine 600mg capsule: Information for the users. Retrieved from https://www.medicines.org.uk/emc/files/pil.11586.pdf
  42. ^ a b c Accord Healthcare Ltd. (2020). Carbocisteine 375mg capsules: Information for the patients. Retrieved from https://www.medicines.org.uk/emc/files/pil.3151.pdf
  43. ^ a b Yasir, Muhammad; Goyal, Amandeep; Bansal, Pankaj; Sonthalia, Sidharth (2021), "Corticosteroid Adverse Effects", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30285357, retrieved 2021-03-14
  44. ^ a b c d e "Penicillins, Cephalosporins, and Other β-Lactam Antibiotics | Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  45. ^ a b c d "Antibiotic Classification & Mechanism – Basic Science – Orthobullets". www.orthobullets.com. Retrieved 2021-03-14.
  46. ^ a b c d Kapoor, Garima; Saigal, Saurabh; Elongavan, Ashok (2017). "Action and resistance mechanisms of antibiotics: A guide for clinicians". Journal of Anaesthesiology Clinical Pharmacology. 33 (3): 300–305. doi:10.4103/joacp.JOACP_349_15. PMC 5672523. PMID 29109626.
  47. ^ a b c d e f g "Chapter 44. Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, Streptogramins, & Linezolid | Katzung & Trevor's Pharmacology: Examination & Board Review, 10e | AccessPharmacy | McGraw-Hill Medical". accesspharmacy.mhmedical.com. Retrieved 2021-03-14.
  48. ^ Patel, Parth H.; Hashmi, Muhammad F. (2021), "Macrolides", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31855339, retrieved 2021-03-14
  49. ^ Chopra, Ian; Roberts, Marilyn (June 2001). "Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance". Microbiology and Molecular Biology Reviews. 65 (2): 232–260. doi:10.1128/MMBR.65.2.232-260.2001. PMC 99026. PMID 11381101.
  50. ^ Evans, Justin; Hannoodee, Maryam; Wittler, Micah (2021), "Amoxicillin Clavulanate", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30844191, retrieved 2021-03-14
  51. ^ NHS Bolton. (2018) List of inhalers used in COPD [Brochure]http://www.boltonft.nhs.uk/wp-content/uploads/2019/02/COPD-Inhalers-Identification-Guide.pdf
  52. ^ Zhang, Shiyuan; King, Denise; Rosen, Virginia M.; Ismaila, Afisi S. (26 February 2020). "Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review". International Journal of Chronic Obstructive Pulmonary Disease. 15: 417–438. doi:10.2147/COPD.S234823. PMC 7049753. PMID 32161454.
  53. ^ Cazzola, Mario; Matera, Maria Gabriella (2016). "Fixed-Dose Combination Inhalers". Pharmacology and Therapeutics of Asthma and COPD. Handbook of Experimental Pharmacology. Vol. 237. pp. 117–129. doi:10.1007/164_2016_66. ISBN 978-3-319-52173-2. PMID 27783268.
  54. ^ Dima, Alexandra L.; Hernandez, Gimena; Cunillera, Oriol; Ferrer, Montserrat; de Bruin, Marijn (April 2015). "Asthma inhaler adherence determinants in adults: systematic review of observational data". European Respiratory Journal. 45 (4): 994–1018. doi:10.1183/09031936.00172114. hdl:2164/7631. PMID 25504997. S2CID 14861322.
  55. ^ Jardim, Jose R; Nascimento, Oliver A. (April 2019). "The Importance of Inhaler Adherence to Prevent COPD Exacerbations". Medical Sciences. 7 (4): 54. doi:10.3390/medsci7040054. PMC 6524014. PMID 30939829.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Commonly_prescribed_drugs&oldid=1189508623"